A3P Biomedical Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
30
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$6.64M
- Investors
-
4
A3P Biomedical General Information
Description
Developer of a blood-based diagnostic screening test designed to improve early detection and risk stratification of aggressive prostate cancer. The company offers a clinically validated algorithm that integrates protein biomarkers, genetic markers, and clinical data, enabling healthcare providers to identify men at risk of clinically significant prostate cancer with improved accuracy.
Contact Information
Website
www.a3p.comCorporate Office
- Kungsgatan 24
- 111 35 Stockholm
- Sweden
Corporate Office
- Kungsgatan 24
- 111 35 Stockholm
- Sweden
A3P Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 06-Mar-2025 | $6.64M | Completed | Generating Revenue | ||
| 3. IPO | Cancelled | Generating Revenue | ||||
| 2. Early Stage VC | 05-May-2022 | $41.5M | $53.9M | Completed | Generating Revenue | |
| 1. Early Stage VC | 21-Oct-2020 | $12.4M | $12.4M | Completed | Startup |
A3P Biomedical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
A3P Biomedical Patents
A3P Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4195211-A1 | Certainty estimation in medical measurements | Pending | 08-Dec-2021 | ||
| US-20230178251-A1 | Certainty estimation in medical measurements | Inactive | 08-Dec-2021 | ||
| EP-4195212-A1 | Certainty-based medical conclusion model adaptation | Pending | 08-Dec-2021 | ||
| US-20230187081-A1 | Certainty-based medical conclusion model adaptation | Inactive | 08-Dec-2021 | ||
| AU-2022354579-A1 | Method and system for management of medical care resources | Inactive | 01-Oct-2021 | G16H10/40 |
A3P Biomedical Signals
A3P Biomedical Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Inbox Capital | Venture Capital | Minority | ||
| Östersjöstiftelsen | Limited Partner | Minority | ||
| Stena Sessan | Limited Partner | Minority | ||
| TomEqt Private | Venture Capital | Minority |
A3P Biomedical Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| A23 Lab | Uppsala, Sweden | 2018 |
A3P Biomedical FAQs
-
When was A3P Biomedical founded?
A3P Biomedical was founded in 2018.
-
Where is A3P Biomedical headquartered?
A3P Biomedical is headquartered in Stockholm, Sweden.
-
What is the size of A3P Biomedical?
A3P Biomedical has 30 total employees.
-
What industry is A3P Biomedical in?
A3P Biomedical’s primary industry is Diagnostic Equipment.
-
Is A3P Biomedical a private or public company?
A3P Biomedical is a Private company.
-
What is A3P Biomedical’s current revenue?
The current revenue for A3P Biomedical is .
-
How much funding has A3P Biomedical raised over time?
A3P Biomedical has raised $53.9M.
-
Who are A3P Biomedical’s investors?
Inbox Capital, Östersjöstiftelsen, Stena Sessan, and TomEqt Private have invested in A3P Biomedical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process